Sarepta Halts Development of Next-Gen DMD Drug, Reports Robust Elevidys Sales

The investigational therapy, vesleteplirsen, had been positioned as an updated version of Sarepta’s original exon 51-skipping Duchenne muscular dystrophy drug Exondys 51.